|
Difference in clot lysis following continuous-wave ultrasound exposure. |
||||||
| Intensity (W/cm2) Time (Min) |
US+SK (n = 6) |
Control (n = 6) |
P-value |
US+r-PA (n = 6) |
Control (n = 6) |
P-value |
|
|
||||||
| 0.0125 |
||||||
| 20 |
13 (11–29) |
13 (11–29) |
0.69 |
7 (5–11) |
6 (4 – 9) |
0.08 |
| 40 |
27 (19–47) |
23 (21–36) |
0.25 |
16 (9–22) |
12 (7–25) |
0.25 |
| 60 |
43 (22–59) |
31 (23–54) |
0.12 |
22 (14–42) |
22 (10–43) |
0.46 |
| 0.025 |
||||||
| 20 |
15 (13–26) |
16 (13–31) |
0.34 |
9 (5–12) |
7 (3–10) |
0.25 |
| 40 |
25 (18–33) |
22 (19–40) |
0.60 |
16 (10–19) |
15 (7–17) |
0.17 |
| 60 |
34 (21–58) |
30 (23–49) |
0.25 |
36 (13–37) |
27 (10–37) |
0.12 |
| 0.05 |
||||||
| 20 |
15 (12–27) |
17 (15–21) |
0.69 |
8 (4–10) |
7 (5–10) |
0.46 |
| 40 |
21 (18–35) |
25 (21–36) |
0.08 |
16 (13–19) |
12 (11–22) |
0.34 |
| 60 |
39 (28–52) |
36 (27–52) |
0.46 |
26 (20–30) |
24 (17–28) |
<0.05 |
| 0.1 |
||||||
| 20 |
18 (13–27) |
15 (10–31) |
0.69 |
7 (6–10) |
8 (4–9) |
0.50 |
| 40 |
22 (19–37) |
21 (15–42) |
0.35 |
15 (10–18) |
17 (3–12) |
0.92 |
| 60 |
32 (25–46) |
29 (20–49) |
0.35 |
28 (23–34) |
24 (13–39) |
0.60 |
| 0.15 |
||||||
| 20 |
17 (14–27) |
17 (13–24) |
0.60 |
7 (5–11) |
7 (5–8) |
0.25 |
| 40 |
28 (19–38) |
23 (16–34) |
0.17 |
15 (14–17) |
15 (11–18) |
0.60 |
| 60 |
35 (21–44) |
39 (23–49) |
0.12 |
28 (20–41) |
25 (16–37) |
0.75 |
| 0.3 |
||||||
| 20 |
16 (14–17) |
17 (13–25) |
0.69 |
8 (3–12) |
7 (2–11) |
0.12 |
| 40 |
26 (19–48) |
25 (18–35) |
0.25 |
14 (12–29) |
13 (8–21) |
< 0.05 |
| 60 |
38 (37–58) |
35 (22–62) |
0.46 |
30 (24–51) |
22 (15–39) |
< 0.05 |
| 0.6 |
||||||
| 20 |
14 (5–16) |
13 (9–16) |
0.92 |
29 (18–35) |
25 (18–31) |
0.08 |
| 40 |
19 (10–23) |
17 (12–21) |
0.60 |
31 (19–52) |
27 (16–43) |
< 0.05 |
| 60 |
23 (14–26) |
21 (16–26) |
0.92 |
41 (28–57) |
33 (22–44) |
< 0.05 |
| 0.9 |
||||||
| 20 |
26 (18–29) |
27 (22–31) |
< 0.05 |
23 (18–29) |
20 (14–29) |
<0.05 |
| 40 |
34 (30–42) |
36 (27–42) |
< 0.05 |
44 (31–47) |
39 (25–42) |
< 0.05 |
| 60 |
38 (30–42) |
42 (33–51) |
< 0.05 |
50 (43–60) |
43 (39–45) |
< 0.05 |
| 1.2 |
||||||
| 20 |
26 (22–29) |
29 (26–34) |
< 0.05 |
17 (14–23) |
9 (8–10) |
< 0.05 |
| 40 |
32 (28–33) |
35 (30–38) |
< 0.05 |
36 (26–38) |
21 (19–22) |
< 0.05 |
| 60 |
32 (30–37) |
41 (37–44) |
< 0.05 |
42 (36–48) |
32 (25–35) |
< 0.05 |
|
Clot lysis (%) of clots exposed to streptokinase concomitantly with continuous-wave ultrasound at different intensities (n = 6 for each intensity) for one hour (US+SK) and clots exposed to streptokinase alone (n = 6 for each intensity, (control clots)) and in clots exposed to reteplase concomitantly with continuous-wave ultrasound at different intensities (n = 6 for each intensity) for one hour (US-r-PA) and reteplase alone (n = 6 for each intensity, (control clots)). Results are presented as medians and 5th – 95th percentiles. Wilcoxon's signed rank test was used to assess statistical difference. | ||||||
Härdig et al. BMC Cardiovascular Disorders 2008 8:19 doi:10.1186/1471-2261-8-19 |
||||||